Muscular polyarteritis nodosa [0.03%]
肌节多动脉炎
Kosuke Ishizuka,Yoshiyuki Ohira,Mitsuyasu Ohta
Kosuke Ishizuka
Gabrio Bassotti
Gabrio Bassotti
Carlo Bellini
Carlo Bellini
Kamran Abbasi,Parveen Ali,Virginia Barbour et al.
Kamran Abbasi et al.
Ultrasound-guided nerve blocks: expert opinion statement on patient monitoring in the emergency department setting [0.03%]
急诊科超声引导周围神经阻滞的患者监测专家意见书
Lachlan Driver,Leland Perice,Joseph R Brown et al.
Lachlan Driver et al.
Takumi Nomura,Takeshi Takahashi,Kento Ko et al.
Takumi Nomura et al.
Tango between obesogenic environment and metabolic dysfunction-associated steatotic liver disease (MASLD): shifting towards earlier detection [0.03%]
肥胖环境与代谢功能异常相关脂肪性肝病(MASLD)之间的探戈：转向早期检测
Harshitha Shanmugam,Agostino Di Ciaula,Mohamad Khalil et al.
Harshitha Shanmugam et al.
Obesity prevalence is increasing worldwide, and drives the rising prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), currently the most prevalent chronic liver disease in all age groups. MASLD, like obesity, is ...
GLP-1 and GIP agonists in diabetes and obesity and the rise of dyspepsia [0.03%]
糖尿病和肥胖症中的GLP-1和GIP激动剂及消化不良的增加
Maria Masulli,Jan Tack,Giuseppe Esposito et al.
Maria Masulli et al.
Glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists, such as tirzepatide, have transformed the management of type 2 diabetes and obesity through durable glycemic contr...